Phase 2 Randomized, Placebo-Controlled Clinical Trial of Recombinant Human Growth Hormone (rhGH) During Rehabilitation From Traumatic Brain Injury
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Traumatic brain injury (TBI) is a major cause of death and disability, but there are currently no therapies with proven efficacy for optimizing regeneration of repair during rehabilitation. Using standard stimulation tests, as many as 40-50% of survivors of severe TBI have deficiency of one or more pituitary hormones. Of these, the somatotropic axis is the most commonly affected, with Growth Hormone (GH) deficiency affecting ~20% of persons with severe TBI. Treatment with recombinant human Growth Hormone (rhGH) is generally effective in reversing the effects of acquired GH deficiency, but there is no evidence documenting functional or neurocognitive improvement after GH replacement in TBI patients. As a consequence, screening for GH deficiency and GH replacement when deficiency is found is not routinely performed as part of the rehabilitation of TBI survivors. Given that most of the recovery after TBI occurs within the first 6-12 months after injury and IGF-1 and GH are part of a coordinated restorative neurotrophic system, we hypothesized that patients will optimally benefit from GH therapy during the window of maximal neuroregenerative activity. We performed a Phase IIa, randomized, double-blind, placebo-controlled feasibility trial of recombinant human Growth Hormone (rhGH), starting at discharge from an inpatient rehabilitation unit, with follow up at 6 and 12 months. Our primary hypothesis was that treatment with rhGH in the subacute period would result in improved functional outcomes 6 months after injury. Our secondary hypothesis proposed that treatment with rhGH would increase IGF-1 levels and be well tolerated. Sixty-three subjects were randomized, and 40 completed the trial. At baseline, there was no correlation between IGF-1 levels and peak GH levels after L-arginine stimulation. IGF-1 levels increased after rhGH treatment, but it took longer than 1 month for levels to be higher than for placebo-treated patients. rhGH therapy was well-tolerated. The rhGH group was no different from placebo in the Disability Rating Scale, Glasgow Outcome Scale-Extended, or neuropsychological function. However, a trend toward greater improvement from baseline in Functional Independence Measure (FIM) was noted in the rhGH treated group. Future studies should include longer treatment periods, faster titration of rhGH, and larger sample sizes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review
Carroll, P. V., Christ the members of Growth Hormon, E. R., Bengtsson, B. Å., Carlsson, L., Christiansen, J. S., Clemmons, D., Hintz, R., Ho, K., Laron, Z., Sizonenko, P., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.2.4594 · Cited by 822
The Mayo Classification System for Traumatic Brain Injury Severity
Malec, J. F., Brown, A. W., Leibson, C. L., Flaada, J. T., Mandrekar, J. N., Diehl, N. N., & Perkins, P. K. (2007) · Journal of Neurotrauma · doi:10.1089/neu.2006.0245 · Cited by 669
Insulin-like growth factor I is required for vessel remodeling in the adult brain.
Lopez-Lopez, C., LeRoith, D., & Torres-Aleman, I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400337101 · Cited by 385 · cited 2×
“In the cortical stab injury model, blockade of IGF1 by an anti-IGF-1 antibody reduces neovascularization at the wound site (30).”
BackgroundAimaretti, G., Ambrosio, M. R., Di Somma, C., Fusco, A., Cannavò, S., Gasperi, M., Scaroni, C., De Marinis, L., Benvenga, S., Uberti, E. C. D., et al. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02094.x · Cited by 339
Occurrence of pituitary dysfunction following traumatic brain injury
Bondanelli, M., De Marinis, L., Ambrosio, M. R., Monesi, M., Valle, D., Zatelli, M. C., Fusco, A., Bianchi, A., Farneti, M., & Degli, E. C. I. (2004) · Journal of Neurotrauma · doi:10.1089/0897715041269713 · Cited by 322
Leal‐Cerro, A., Flores, J. M., Rincon, M., Murillo, F., Pujol, M., Garcia‐Pesquera, F., Dieguez, C., & Casanueva, F. F. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02250.x · Cited by 199 · cited 1×
“Treating only patients who have GH deficiency defined using stimulation tests (either glucagon or GHRH+ L-arginine, which were developed for non-trauma populations), as was done in a past clinical trial, may be too conservative (14), as it may deny therapy to many patients with hypothalamic dysfunction and serum IGF-1…”
Saatman, K. E., Contreras, P. C., Smith, D. H., Raghupathi, R., McDermott, K. L., Fernandez, S. C., Sanderson, K. L., Voddi, M., & McIntosh, T. K. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6629 · Cited by 185
Effect of growth hormone replacement therapy on cognition after traumatic brain injury
High, W. M., Briones-Galang, M., Clark, J. A., Gilkison, C., Mossberg, K. A., Zgaljardic, D. J., Masel, B. E., & Urban, R. J. (2010) · Journal of Neurotrauma · doi:10.1089/neu.2009.1253 · Cited by 176 · cited 1×
“(11) randomized 23 subjects to either GH replacement or placebo.”
BackgroundGrowth hormone as a neuronal rescue factor during recovery from CNS injury
Scheepens, A., Sirimanne, E. S., Breier, B. H., Clark, R. G., Gluckman, P. D., & Williams, C. E. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00109-9 · Cited by 174 · cited 1×
“This is particularly the case when therapy is administered early after injury (21, 23).”
BackgroundAgha, A., Walker, D., Perry, L., Drake, W. M., Chew, S. L., Jenkins, P. J., Grossman, A. B., & Monson, J. P. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02688.x · Cited by 113 · cited 1×
“Of these, the somatotropic axis is the most vulnerable, with estimates of Growth Hormone (GH) deficiency affecting ∼20% of persons with severe TBI (3).”
BackgroundReimunde, P., Quintana, A., Castañón, B., Casteleiro, N., Vilarnovo, Z., Otero, A., Devesa, A., Otero-Cepeda, X. L., & Devesa, J. (2011) · Brain Injury · doi:10.3109/02699052.2010.536196 · Cited by 100
Growth hormone replacement therapy in patients with traumatic brain injury
Moreau, O. K., Cortet-Rudelli, C., Yollin, E., Merlen, E., Daveluy, W., & Rousseaux, M. (2013) · Journal of Neurotrauma · doi:10.1089/neu.2012.2705 · Cited by 94 · cited 1×
“(12) conducted an open-label study on 23 TBI patients with GH deficiency (average 7.”
BackgroundGrowth hormone (GH) and brain trauma
Devesa, J., Reimunde, P., Devesa, P., Barberá, M., & Arce, V. (2013) · Hormones and Behavior · doi:10.1016/j.yhbeh.2012.02.022 · Cited by 87
Cited by
Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions
Bhalla, S., Mehan, S., Khan, A., & Rehman, M. U. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104896 · Cited by 108
Yuen, K. C. J., Masel, B. E., Reifschneider, K. L., Sheffield-Moore, M., Urban, R. J., & Pyles, R. B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa398 · Cited by 24
Experience of a Pituitary Clinic for US Military Veterans With Traumatic Brain Injury
Lee, J., Anderson, L. J., Migula, D., Yuen, K. C. J., McPeak, L., & Garcia, J. M. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab005 · Cited by 17
“Hormone replacement has proven benefits in other deficient populations, with some select studies having also proven these benefits in TBI patients [40-43].”
BackgroundFlores-Sandoval, C., Teasell, R., MacKenzie, H. M., McIntyre, A., Barua, U., Mehta, S., Bayley, M., & Bateman, E. A. (2024) · Journal of Head Trauma Rehabilitation · doi:10.1097/htr.0000000000000984 · Cited by 16
“26 , 31 Melatonin was examined in 2 RCTs. Grima et al 28 found that melatonin significantly improved anxiety compared to placebo, while Kemp et al 46 found no changes from baseline to postintervention in favor of melatonin or amitriptyline for mood.”
Endocrine Abnormalities in Children with Traumatic Brain Injury at a Tertiary Care Center
Rao, A., Laghari, A. A., Bari, I., Khalid, M. U., Kirmani, S., & Bari, M. E. (2023) · Cureus · doi:10.7759/cureus.34131 · Cited by 4
“However, instances of hyperglycemia and fluid retention in GH replacement therapies and the epileptic potential of IGF-1therapy have rendered GH infusion unsuitable for children [19-22].”
Background
Metadata
- Authors
- Dubiel, R., Callender, L., Dunklin, C., Harper, C., Bennett, M., Kreber, L., Auchus, R., & Diaz-Arrastia, R.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2018-09-10
- Volume
- 9
- Pages
- 520-520
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2892056543
- Cited by
- 21
- References
- 14
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.